Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies.

Angus L, Smid M, Wilting SM, van Riet J, Van Hoeck A, Nguyen L, Nik-Zainal S, Steenbruggen TG, Tjan-Heijnen VCG, Labots M, van Riel JMGH, Bloemendal HJ, Steeghs N, Lolkema MP, Voest EE, van de Werken HJG, Jager A, Cuppen E, Sleijfer S, Martens JWM.

Nat Genet. 2019 Sep 30. doi: 10.1038/s41588-019-0507-7. [Epub ahead of print]

PMID:
31570896
2.

Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer.

Belderbos BPS, Sieuwerts AM, Hoop EO, Mostert B, Kraan J, Hamberg P, Van MN, Beaufort CM, Onstenk W, van Soest RJ, Martens J, Sleijfer S, de Wit R, Mathijssen RHJ, Lolkema MP.

Eur J Cancer. 2019 Sep 19;121:48-54. doi: 10.1016/j.ejca.2019.08.005. [Epub ahead of print]

PMID:
31542641
3.

Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel.

de Kruijff IE, Sieuwerts AM, Onstenk W, Kraan J, Smid M, Van MN, van der Vlugt-Daane M, Hoop EO, Mathijssen RHJ, Lolkema MP, de Wit R, Hamberg P, Meulenbeld HJ, Beeker A, Creemers GJ, Martens JWM, Sleijfer S.

Cancers (Basel). 2019 Aug 20;11(8). pii: E1212. doi: 10.3390/cancers11081212.

4.

Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting.

Aluwini SS, Mehra N, Lolkema MP, Oprea-Lager DE, Yakar D, Stoevelaar H, van der Poel H; Dutch Oligometastatic Prostate Cancer Working Group, Busstra M, de Jong IJ, de Reijke T, de Vries K, Heijmink S, Jenster G, Klaver S, Kneppers J, Lavalaye J, Leyten G, Moonen L, Nagaraj J, Noordzij W, Osanto S, Oving I, Schaake E, Scheenen T, Schoots I, Sedelaar M, Somford D, van den Berkmortel F, van der Hulle T, van der Voort van Zyp J, van Leeuwen P, van Moorselaar J, van Oort I, Vogel W, Westgeest H.

Eur Urol Oncol. 2019 Aug 7. pii: S2588-9311(19)30113-0. doi: 10.1016/j.euo.2019.07.010. [Epub ahead of print]

PMID:
31401014
5.

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.

Bardia A, Gounder M, Rodon J, Janku F, Lolkema MP, Stephenson JJ, Bedard PL, Schuler M, Sessa C, LoRusso P, Thomas M, Maacke H, Evans H, Sun Y, Tan DSW.

Oncologist. 2019 Aug 8. pii: theoncologist.2019-0297. doi: 10.1634/theoncologist.2019-0297. [Epub ahead of print]

PMID:
31395751
6.

Novel Treatment Options in the Management of Metastatic Castration-naïve Prostate Cancer; Which Treatment Modality to Choose?

Belderbos BPS, de Wit R, Lolkema MPJ, Mathijssen RHJ, van Soest RJ.

Ann Oncol. 2019 Jul 24. pii: mdz210. doi: 10.1093/annonc/mdz210. [Epub ahead of print]

PMID:
31340031
7.

[Genetic testing in patients with cancer; new developments].

Ausems MGEM, Oosterwijk JC, Nielsen M, Lolkema MP, Hoogerbrugge N, Ligtenberg MJL.

Ned Tijdschr Geneeskd. 2019 May 20;163. pii: D3801. Dutch.

PMID:
31140768
8.

Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies.

de Jonge MJA, Steeghs N, Lolkema MP, Hotte SJ, Hirte HW, van der Biessen DAJ, Abdul Razak AR, De Vos FYFL, Verheijen RB, Schnell D, Pronk LC, Jansen M, Siu LL.

Target Oncol. 2019 Feb;14(1):43-55. doi: 10.1007/s11523-018-00617-1.

9.

Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520.

Verheijen RB, van der Biessen DAJ, Hotte SJ, Siu LL, Spreafico A, de Jonge MJA, Pronk LC, De Vos FYFL, Schnell D, Hirte HW, Steeghs N, Lolkema MP.

Target Oncol. 2019 Feb;14(1):67-74. doi: 10.1007/s11523-018-00618-0.

10.

Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer: A randomized drug-drug interaction study.

Belderbos BPS, Hussaarts KGAM, van Harten LJ, Oomen-de Hoop E, de Bruijn P, Hamberg P, van Alphen RJ, Haberkorn BCM, Lolkema MP, de Wit R, van Soest RJ, Mathijssen RHJ.

Br J Clin Pharmacol. 2019 May;85(5):986-992. doi: 10.1111/bcp.13889. Epub 2019 Mar 21.

PMID:
30737835
11.

High-throughput isolation of circulating tumor DNA: a comparison of automated platforms.

van Dessel LF, Vitale SR, Helmijr JCA, Wilting SM, van der Vlugt-Daane M, Oomen-de Hoop E, Sleijfer S, Martens JWM, Jansen MPHM, Lolkema MP.

Mol Oncol. 2019 Feb;13(2):392-402. doi: 10.1002/1878-0261.12415. Epub 2018 Dec 22.

12.

A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors.

Atrafi F, Groen HJM, Byers LA, Garralda E, Lolkema MP, Sangha RS, Viteri S, Chae YK, Camidge DR, Gabrail NY, Hu B, Tian T, Nuthalapati S, Hoening E, He L, Komarnitsky P, Calles A.

Clin Cancer Res. 2019 Jan 15;25(2):496-505. doi: 10.1158/1078-0432.CCR-18-2014. Epub 2018 Oct 16.

PMID:
30327308
13.

Self-reported quality of life and hope in phase-I trial participants: An observational prospective cohort study.

van der Biessen DA, Oldenmenger WH, van der Helm PG, Klein D, Oomen-de Hoop E, Mathijssen RH, Lolkema MP, de Jonge MJ.

Eur J Cancer Care (Engl). 2018 Nov;27(6):e12908. doi: 10.1111/ecc.12908. Epub 2018 Sep 4.

PMID:
30179287
14.

Cell-free DNA in Advanced Prostate Cancer: A Biomarker Revolution Under Way?

van Soest RJ, Tombal B, Lolkema MP, de Wit R.

Eur Urol. 2018 Sep;74(3):292-293. doi: 10.1016/j.eururo.2018.03.002. Epub 2018 Mar 19. No abstract available.

PMID:
29566958
15.

An In-Depth Evaluation of the Validity and Logistics Surrounding the Testing of AR-V7 mRNA Expression in Circulating Tumor Cells.

Sieuwerts AM, Mostert B, van der Vlugt-Daane M, Kraan J, Beaufort CM, Van M, Prager WJC, De Laere B, Beije N, Hamberg P, Westgeest HM, Tascilar M, Dirix LY, Onstenk W, de Wit R, Lolkema MP, Mathijssen RHJ, Martens JWM, Sleijfer S.

J Mol Diagn. 2018 May;20(3):316-325. doi: 10.1016/j.jmoldx.2018.01.008. Epub 2018 Feb 21.

PMID:
29474983
16.

Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug-Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients.

Belderbos BPS, Bins S, van Leeuwen RWF, Oomen-de Hoop E, van der Meer N, de Bruijn P, Hamberg P, Overkleeft ENM, van der Deure WM, Lolkema MP, de Wit R, Mathijssen RHJ.

Clin Cancer Res. 2018 Feb 1;24(3):541-546. doi: 10.1158/1078-0432.CCR-17-2336. Epub 2017 Nov 17.

18.

Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study.

Weeber F, Cirkel GA, Hoogstraat M, Bins S, Gadellaa-van Hooijdonk CGM, Ooft S, van Werkhoven E, Willems SM, van Stralen M, Veldhuis WB, Besselink NJM, Horlings HM, Steeghs N, de Jonge MJ, Langenberg MHG, Wessels LFA, Cuppen EPJG, Schellens JH, Sleijfer S, Lolkema MP, Voest EE.

Oncotarget. 2017 Mar 8;8(33):55582-55592. doi: 10.18632/oncotarget.16029. eCollection 2017 Aug 15.

19.

Understanding how coping strategies and quality of life maintain hope in patients deliberating phase I trial participation.

van der Biessen DA, van der Helm PG, Klein D, van der Burg S, Mathijssen RH, Lolkema MP, de Jonge MJ.

Psychooncology. 2018 Jan;27(1):163-170. doi: 10.1002/pon.4487. Epub 2017 Jul 26.

PMID:
28665008
20.

Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.

Rijnders M, de Wit R, Boormans JL, Lolkema MPJ, van der Veldt AAM.

Eur Urol. 2017 Sep;72(3):411-423. doi: 10.1016/j.eururo.2017.06.012. Epub 2017 Jun 20. Review.

PMID:
28645491
21.

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity.

Meulendijks D, Jacob W, Voest EE, Mau-Sorensen M, Martinez-Garcia M, Taus A, Fleitas T, Cervantes A, Lolkema MP, Langenberg MHG, De Jonge MJ, Sleijfer S, Han JY, Calles A, Felip E, Kim SW, Schellens JHM, Wilson S, Thomas M, Ceppi M, Meneses-Lorente G, James I, Vega-Harring S, Dua R, Nguyen M, Steiner L, Adessi C, Michielin F, Bossenmaier B, Weisser M, Lassen UN.

Clin Cancer Res. 2017 Sep 15;23(18):5406-5415. doi: 10.1158/1078-0432.CCR-17-0812. Epub 2017 Jun 9.

22.

Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT).

Ubink I, Bloemendal HJ, Elias SG, Brink MA, Schwartz MP, Holierhoek YCW, Verheijen PM, Boerman AW, Mathijssen RHJ, de Leng WWJ, de Weger RA, van Grevenstein WMU, Koopman M, Lolkema MP, Kranenburg O, Borel Rinkes IHM.

BMC Cancer. 2017 Apr 19;17(1):282. doi: 10.1186/s12885-017-3264-y.

23.

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.

van Geel RMJM, Tabernero J, Elez E, Bendell JC, Spreafico A, Schuler M, Yoshino T, Delord JP, Yamada Y, Lolkema MP, Faris JE, Eskens FALM, Sharma S, Yaeger R, Lenz HJ, Wainberg ZA, Avsar E, Chatterjee A, Jaeger S, Tan E, Maharry K, Demuth T, Schellens JHM.

Cancer Discov. 2017 Jun;7(6):610-619. doi: 10.1158/2159-8290.CD-16-0795. Epub 2017 Mar 31.

24.

Application of circulating tumor DNA in prospective clinical oncology trials - standardization of preanalytical conditions.

van Dessel LF, Beije N, Helmijr JC, Vitale SR, Kraan J, Look MP, de Wit R, Sleijfer S, Jansen MP, Martens JW, Lolkema MP.

Mol Oncol. 2017 Mar;11(3):295-304. doi: 10.1002/1878-0261.12037. Epub 2017 Feb 22.

25.

Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial.

Cirkel GA, Hamberg P, Sleijfer S, Loosveld OJL, Dercksen MW, Los M, Polee MB, van den Berkmortel F, Aarts MJ, Beerepoot LV, Groenewegen G, Lolkema MP, Tascilar M, Portielje JEA, Peters FPJ, Klümpen HJ, van der Noort V, Haanen JBAG, Voest EE; Dutch WIN-O Consortium.

JAMA Oncol. 2017 Apr 1;3(4):501-508. doi: 10.1001/jamaoncol.2016.5202.

PMID:
27918762
26.

Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies.

Bins S, Cirkel GA, Gadellaa-Van Hooijdonk CG, Weeber F, Numan IJ, Bruggink AH, van Diest PJ, Willems SM, Veldhuis WB, van den Heuvel MM, de Knegt RJ, Koudijs MJ, van Werkhoven E, Mathijssen RH, Cuppen E, Sleijfer S, Schellens JH, Voest EE, Langenberg MH, de Jonge MJ, Steeghs N, Lolkema MP.

Oncologist. 2017 Jan;22(1):33-40. doi: 10.1634/theoncologist.2016-0085. Epub 2016 Sep 23.

27.

Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients.

Verheijen RB, Bins S, Mathijssen RH, Lolkema MP, van Doorn L, Schellens JH, Beijnen JH, Langenberg MH, Huitema AD, Steeghs N; Dutch Pharmacology Oncology Group.

Clin Cancer Res. 2016 Dec 1;22(23):5738-5746. Epub 2016 Jul 28.

28.

Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.

Curigliano G, Gómez Pardo P, Meric-Bernstam F, Conte P, Lolkema MP, Beck JT, Bardia A, Martínez García M, Penault-Llorca F, Dhuria S, Tang Z, Solovieff N, Miller M, Di Tomaso E, Hurvitz SA.

Breast. 2016 Aug;28:191-8. doi: 10.1016/j.breast.2016.06.008. Epub 2016 Jun 20.

29.

The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies.

Cirkel GA, Weeber F, Bins S, Gadellaa-van Hooijdonk CG, van Werkhoven E, Willems SM, van Stralen M, Veldhuis WB, Ubink I, Steeghs N, de Jonge MJ, Langenberg MH, Schellens JH, Sleijfer S, Lolkema MP, Voest EE.

Ann Oncol. 2016 Aug;27(8):1638-43. doi: 10.1093/annonc/mdw223. Epub 2016 May 27.

PMID:
27234642
30.

Unsolicited findings of next-generation sequencing for tumor analysis within a Dutch consortium: clinical daily practice reconsidered.

Bijlsma RM, Bredenoord AL, Gadellaa-Hooijdonk CG, Lolkema MP, Sleijfer S, Voest EE, Ausems MG, Steeghs N.

Eur J Hum Genet. 2016 Oct;24(10):1496-500. doi: 10.1038/ejhg.2016.27. Epub 2016 Apr 13.

31.

A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors.

Milojkovic Kerklaan B, Slater S, Flynn M, Greystoke A, Witteveen PO, Megui-Roelvink M, de Vos F, Dean E, Reyderman L, Ottesen L, Ranson M, Lolkema MP, Plummer R, Kristeleit R, Evans TR, Schellens JH.

Invest New Drugs. 2016 Jun;34(3):329-37. doi: 10.1007/s10637-016-0344-9. Epub 2016 Apr 2.

PMID:
27039386
32.

Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.

de Leng WW, Gadellaa-van Hooijdonk CG, Barendregt-Smouter FA, Koudijs MJ, Nijman I, Hinrichs JW, Cuppen E, van Lieshout S, Loberg RD, de Jonge M, Voest EE, de Weger RA, Steeghs N, Langenberg MH, Sleijfer S, Willems SM, Lolkema MP.

PLoS One. 2016 Feb 26;11(2):e0149405. doi: 10.1371/journal.pone.0149405. eCollection 2016.

33.

A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies.

Cirkel GA, Kerklaan BM, Vanhoutte F, Van der Aa A, Lorenzon G, Namour F, Pujuguet P, Darquenne S, de Vos FY, Snijders TJ, Voest EE, Schellens JH, Lolkema MP.

Invest New Drugs. 2016 Apr;34(2):184-92. doi: 10.1007/s10637-015-0320-9. Epub 2016 Jan 20.

34.

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.

Dolly SO, Wagner AJ, Bendell JC, Kindler HL, Krug LM, Seiwert TY, Zauderer MG, Lolkema MP, Apt D, Yeh RF, Fredrickson JO, Spoerke JM, Koeppen H, Ware JA, Lauchle JO, Burris HA 3rd, de Bono JS.

Clin Cancer Res. 2016 Jun 15;22(12):2874-84. doi: 10.1158/1078-0432.CCR-15-2225. Epub 2016 Jan 19.

35.

Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBS.

Verheijen RB, Bins S, Thijssen B, Rosing H, Nan L, Schellens JH, Mathijssen RH, Lolkema MP, Beijnen JH, Steeghs N, Huitema AD.

Bioanalysis. 2016;8(2):123-34. doi: 10.4155/bio.15.235. Epub 2015 Dec 10.

PMID:
26652864
36.

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.

Meulendijks D, Jacob W, Martinez-Garcia M, Taus A, Lolkema MP, Voest EE, Langenberg MH, Fleitas Kanonnikoff T, Cervantes A, De Jonge MJ, Sleijfer S, Soerensen MM, Thomas M, Ceppi M, Meneses-Lorente G, James I, Adessi C, Michielin F, Abiraj K, Bossenmaier B, Schellens JH, Weisser M, Lassen UN.

Clin Cancer Res. 2016 Feb 15;22(4):877-85. doi: 10.1158/1078-0432.CCR-15-1683. Epub 2015 Oct 13.

37.

Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours.

Kerklaan BM, Lolkema MP, Devriese LA, Voest EE, Nol-Boekel A, Mergui-Roelvink M, Langenberg M, Mykulowycz K, Stoebenau J, Lane S, Legenne P, Wissel P, Smith DA, Giantonio BJ, Schellens JH, Witteveen PO.

Br J Cancer. 2015 Sep 1;113(5):706-15. doi: 10.1038/bjc.2015.257. Epub 2015 Aug 20.

38.

Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.

Plummer R, Swaisland H, Leunen K, van Herpen CM, Jerusalem G, De Grève J, Lolkema MP, Soetekouw P, Mau-Sørensen M, Nielsen D, Spicer J, Fielding A, So K, Bannister W, Molife LR.

Cancer Chemother Pharmacol. 2015 Oct;76(4):723-9. doi: 10.1007/s00280-015-2836-2. Epub 2015 Aug 5.

PMID:
26242220
39.

Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.

Onstenk W, Sieuwerts AM, Kraan J, Van M, Nieuweboer AJ, Mathijssen RH, Hamberg P, Meulenbeld HJ, De Laere B, Dirix LY, van Soest RJ, Lolkema MP, Martens JW, van Weerden WM, Jenster GW, Foekens JA, de Wit R, Sleijfer S.

Eur Urol. 2015 Dec;68(6):939-45. doi: 10.1016/j.eururo.2015.07.007. Epub 2015 Jul 15.

PMID:
26188394
40.

CopywriteR: DNA copy number detection from off-target sequence data.

Kuilman T, Velds A, Kemper K, Ranzani M, Bombardelli L, Hoogstraat M, Nevedomskaya E, Xu G, de Ruiter J, Lolkema MP, Ylstra B, Jonkers J, Rottenberg S, Wessels LF, Adams DJ, Peeper DS, Krijgsman O.

Genome Biol. 2015 Feb 27;16:49. doi: 10.1186/s13059-015-0617-1.

41.

The role of biological markers of epithelial to mesenchymal transition in oesophageal adenocarcinoma, an immunohistochemical study.

Prins MJ, Ruurda JP, Lolkema MP, Sitarz R, Ten Kate FJ, van Hillegersberg R.

J Clin Pathol. 2015 Jul;68(7):529-35. doi: 10.1136/jclinpath-2015-202962. Epub 2015 Apr 8.

PMID:
25855799
42.

The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation.

Lolkema MP, Bohets HH, Arkenau HT, Lampo A, Barale E, de Jonge MJA, van Doorn L, Hellemans P, de Bono JS, Eskens FALM.

Clin Cancer Res. 2015 May 15;21(10):2297-2304. doi: 10.1158/1078-0432.CCR-14-3258. Epub 2015 Mar 5.

43.

Safety, efficacy, and long-term follow-up evaluation of perioperative epirubicin, Cisplatin, and capecitabine chemotherapy in esophageal resection for adenocarcinoma.

van der Sluis PC, Ubink I, van der Horst S, Boonstra JJ, Voest EE, Ruurda JP, Borel Rinkes IH, Wiezer MJ, Schipper ME, Siersema PD, Los M, Lolkema MP, van Hillegersberg R.

Ann Surg Oncol. 2015 May;22(5):1555-63. doi: 10.1245/s10434-014-4120-9. Epub 2015 Jan 7.

PMID:
25564156
44.

Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib.

Hoogstraat M, Gadellaa-van Hooijdonk CG, Ubink I, Besselink NJ, Pieterse M, Veldhuis W, van Stralen M, Meijer EF, Willems SM, Hadders MA, Kuilman T, Krijgsman O, Peeper DS, Koudijs MJ, Cuppen E, Voest EE, Lolkema MP.

Pigment Cell Melanoma Res. 2015 May;28(3):318-23. doi: 10.1111/pcmr.12347. Epub 2015 Jan 7.

PMID:
25515853
45.

A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function.

Sharma S, Witteveen PO, Lolkema MP, Hess D, Gelderblom H, Hussain SA, Porro MG, Waldron E, Valera SZ, Mu S.

Cancer Chemother Pharmacol. 2015 Jan;75(1):87-95. doi: 10.1007/s00280-014-2612-8. Epub 2014 Nov 7.

PMID:
25377157
46.

CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.

Wissing MD, Coenen JL, van den Berg P, Westgeest HM, van den Eertwegh AJ, van Oort IM, Bos MM, Bergman AM, Hamberg P, Ten Tije AJ, Los M, Lolkema MP, de Wit R, Gelderblom H.

Int J Cancer. 2015 Mar 15;136(6):E760-72. doi: 10.1002/ijc.29231. Epub 2014 Oct 3.

47.

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.

Lankheet NA, Kloth JS, Gadellaa-van Hooijdonk CG, Cirkel GA, Mathijssen RH, Lolkema MP, Schellens JH, Voest EE, Sleijfer S, de Jonge MJ, Haanen JB, Beijnen JH, Huitema AD, Steeghs N.

Br J Cancer. 2014 May 13;110(10):2441-9. doi: 10.1038/bjc.2014.194. Epub 2014 Apr 15.

48.

Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662.

Diekstra MH, Klümpen HJ, Lolkema MP, Yu H, Kloth JS, Gelderblom H, van Schaik RH, Gurney H, Swen JJ, Huitema AD, Steeghs N, Mathijssen RH.

Clin Pharmacol Ther. 2014 Jul;96(1):81-9. doi: 10.1038/clpt.2014.47. Epub 2014 Feb 24.

PMID:
24566734
49.

Adding preoperative radiotherapy plus cetuximab to perioperative chemotherapy for resectable esophageal adenocarcinoma: a single-center prospective phase II trial.

Ubink I, van der Sluis P, Schipper M, Reerink O, Voest E, Borel-Rinkes I, Wijrdeman H, Vleggaar F, Agterof M, Overkleeft E, Siersema P, van Hillegersberg R, Lolkema MP.

Oncologist. 2014 Jan;19(1):32-3. doi: 10.1634/theoncologist.2013-0254. Epub 2013 Dec 12.

50.

Genomic and transcriptomic plasticity in treatment-naive ovarian cancer.

Hoogstraat M, de Pagter MS, Cirkel GA, van Roosmalen MJ, Harkins TT, Duran K, Kreeftmeijer J, Renkens I, Witteveen PO, Lee CC, Nijman IJ, Guy T, van 't Slot R, Jonges TN, Lolkema MP, Koudijs MJ, Zweemer RP, Voest EE, Cuppen E, Kloosterman WP.

Genome Res. 2014 Feb;24(2):200-11. doi: 10.1101/gr.161026.113. Epub 2013 Nov 12.

Supplemental Content

Loading ...
Support Center